The Food and Drug Administration’s regulation of the US OTC drug space is being overhauled through changes to its monograph program made within deadlines set by Congress and a proposal to extend labeling for nonprescription drugs into the digital realm.
However, what access to nonprescription drugs will look like after monograph reform is completed and if “additional conditions for nonprescription...







